Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 5017 results found since Jan 2013.
Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data
CONCLUSION: AQP4+NMOSD in SLE patients is a relapsing and neurologically disabling disorder that can mimic neuropsychiatric manifestations, frequently occurs after the onset of lupus or may predate, responds to immunosuppressants, and necessitates indefinite treatment.PMID:37487596 | DOI:10.1177/09612033231191180
Source: Lupus - July 24, 2023 Category: Rheumatology Authors: Chirag Rajkumar Kopp Chandra Bhushan Prasad Shankar Naidu Vishal Sharma Durga Prasanna Misra Vikas Agarwal Aman Sharma Source Type: research
Radio-immunotherapy by < sup > 188 < /sup > Re-antiCD20 and stable silencing of IGF-IR in Raji cells, new insight in treatment of lymphoma
Gene. 2023 Jul 19:147638. doi: 10.1016/j.gene.2023.147638. Online ahead of print.ABSTRACTHematologic malignancies such as Non-Hodgkin's lymphoma (NHL), remain a serious threat to human health due to their heterogeneity and complexity. The inherent genetic heterogeneity of NHL B-cells, as well as the instability of lymphoma cancer cells, results in drug resistance in lymphoma, posing a fundamental challenge to NHL treatment. Burkitt lymphoma (including Raji cell line) is a rare and highly aggressive form of B-cell NHL. Since overexpression of the insulin-like growth factor-1 receptor (IGF-1R) playing a prominent role in the...
Source: Gene - July 21, 2023 Category: Genetics & Stem Cells Authors: Leila Nasehi Baharak Abdolhossein Zadeh Hossein Rahimi Mohammad Hossein Ghahremani Source Type: research
Bing-Neel syndrome with a paravertebral mass
We report a patient who presented with back pain, weakness, lower extremity numbness, and gait disturbance accompanied by immunoglobulin M paraproteinemia and lymphoplasmacytic lymphoma in the bone marrow. Thoracic and lumbar magnetic resonance imaging revealed a long paravertebral mass around the spinal column, but the direct infiltration could not be proven. The patient was diagnosed with possible Bing-Neel syndrome and managed with bendamustine and rituximab. After chemotherapy, the patient's neurological and radiological findings improved. Magnetic resonance imaging should be considered when the Bing-Neel syndrome diag...
Source: The American Journal of the Medical Sciences - July 20, 2023 Category: General Medicine Authors: Daisuke Suzuki Daisuke Sato Kenji Kikuchi Takuma Suzuki Kunie Sugasawa Soichi Saito Fumiaki Uchimura Yoshihiro Suzuki Source Type: research
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
CONCLUSIONS: Using the MENTOR clinical trial cohort of patients with membranous nephropathy treated with standardized cyclosporine or rituximab, we found that the optimal method to evaluate risk factors for the probability of treatment response was to use anti-PLA2R antibody levels combined with albumin levels after 3 months of treatment, which was significantly better than using antibody levels alone or risk factor evaluation at baseline, with no added benefit of waiting until 6 months of treatment.PMID:37471101 | DOI:10.2215/CJN.0000000000000237
Source: Clinical Journal of the American Society of Nephrology : CJASN - July 20, 2023 Category: Urology & Nephrology Authors: Sean J Barbour Fernando C Fervenza Dilshani Induruwage Paul E Brenchley Brad Rovin Michelle Hladunewich Heather N Reich Richard Lafayette Nabeel Aslam Gerald B Appel Ladan Zand Krzysztof Kiryluk Lili Liu Daniel C Cattran MENTOR Trial investigators Source Type: research
Bing-Neel syndrome with a paravertebral mass
We report a patient who presented with back pain, weakness, lower extremity numbness, and gait disturbance accompanied by immunoglobulin M paraproteinemia and lymphoplasmacytic lymphoma in the bone marrow. Thoracic and lumbar magnetic resonance imaging revealed a long paravertebral mass around the spinal column, but the direct infiltration could not be proven. The patient was diagnosed with possible Bing-Neel syndrome and managed with bendamustine and rituximab. After chemotherapy, the patient's neurological and radiological findings improved. Magnetic resonance imaging should be considered when the Bing-Neel syndrome diag...
Source: The American Journal of the Medical Sciences - July 20, 2023 Category: General Medicine Authors: Daisuke Suzuki Daisuke Sato Kenji Kikuchi Takuma Suzuki Kunie Sugasawa Soichi Saito Fumiaki Uchimura Yoshihiro Suzuki Source Type: research
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
CONCLUSIONS: Using the MENTOR clinical trial cohort of patients with membranous nephropathy treated with standardized cyclosporine or rituximab, we found that the optimal method to evaluate risk factors for the probability of treatment response was to use anti-PLA2R antibody levels combined with albumin levels after 3 months of treatment, which was significantly better than using antibody levels alone or risk factor evaluation at baseline, with no added benefit of waiting until 6 months of treatment.PMID:37471101 | DOI:10.2215/CJN.0000000000000237
Source: Clinical Journal of the American Society of Nephrology : CJASN - July 20, 2023 Category: Urology & Nephrology Authors: Sean J Barbour Fernando C Fervenza Dilshani Induruwage Paul E Brenchley Brad Rovin Michelle Hladunewich Heather N Reich Richard Lafayette Nabeel Aslam Gerald B Appel Ladan Zand Krzysztof Kiryluk Lili Liu Daniel C Cattran MENTOR Trial investigators Source Type: research
Bing-Neel syndrome with a paravertebral mass
We report a patient who presented with back pain, weakness, lower extremity numbness, and gait disturbance accompanied by immunoglobulin M paraproteinemia and lymphoplasmacytic lymphoma in the bone marrow. Thoracic and lumbar magnetic resonance imaging revealed a long paravertebral mass around the spinal column, but the direct infiltration could not be proven. The patient was diagnosed with possible Bing-Neel syndrome and managed with bendamustine and rituximab. After chemotherapy, the patient's neurological and radiological findings improved. Magnetic resonance imaging should be considered when the Bing-Neel syndrome diag...
Source: The American Journal of the Medical Sciences - July 20, 2023 Category: General Medicine Authors: Daisuke Suzuki Daisuke Sato Kenji Kikuchi Takuma Suzuki Kunie Sugasawa Soichi Saito Fumiaki Uchimura Yoshihiro Suzuki Source Type: research
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy
CONCLUSIONS: Using the MENTOR clinical trial cohort of patients with membranous nephropathy treated with standardized cyclosporine or rituximab, we found that the optimal method to evaluate risk factors for the probability of treatment response was to use anti-PLA2R antibody levels combined with albumin levels after 3 months of treatment, which was significantly better than using antibody levels alone or risk factor evaluation at baseline, with no added benefit of waiting until 6 months of treatment.PMID:37471101 | DOI:10.2215/CJN.0000000000000237
Source: Clinical Journal of the American Society of Nephrology : CJASN - July 20, 2023 Category: Urology & Nephrology Authors: Sean J Barbour Fernando C Fervenza Dilshani Induruwage Paul E Brenchley Brad Rovin Michelle Hladunewich Heather N Reich Richard Lafayette Nabeel Aslam Gerald B Appel Ladan Zand Krzysztof Kiryluk Lili Liu Daniel C Cattran MENTOR Trial investigators Source Type: research
Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study
CONCLUSION: Prophylactic TDF up to 6 months after completion of rituximab-based chemotherapy is sufficient in terms of the efficacy and safety of reducing HBV reactivation in patients with resolved HBV.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02585947.PMID:37463687 | PMC:PMC10353911 | DOI:10.3346/jkms.2023.38.e216
Source: J Korean Med Sci - July 18, 2023 Category: General Medicine Authors: Heejoon Jang Su Jong Yu Hong Ghi Lee Tae Min Kim Yun Bin Lee Eun Ju Cho Jeong-Hoon Lee Jung-Hwan Yoon Yoon Jun Kim Source Type: research
